Senior Vice President of Preclinical Development
Metagenomi
Emeryville, United States
Alan received his Bachelor of Science from the University of Leicester and his Ph.D. from the University of Warwick, both in the UK. He then moved to San Francisco and completed a postdoctoral fellowship at the Gladstone Institute of Cardiovascular Disease before embarking on career in industry. Alan has 30 years of experience in drug discovery and development at both biotech and pharmaceutical companies applying protein therapeutics, gene therapy and most recently gene editing to hemophilia and cardiovascular diseases. Following 8 years at Berlex Biosciences and 10 years at Bayer Healthcare, in 2017 he joined Casebia Therapeutics where he built the in vivo gene editing department and initiated and led two CRISPR-Cas9 based in vivo therapeutic programs. In 2019 he joined Metagenomi, a gene editing startup company developing novel gene editing systems. Over the last 4 years at Metagenomi he has built the pre-clinical team and has been instrumental in advancing the companies novel editing systems to successful in vivo editing and in establishing the therapeutic strategy and portfolio of projects.